Patents Examined by Julie Burke
  • Patent number: 6015555
    Abstract: The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor and the antibody is a chimera between the variable region from one animal source and the constant region from a different animal source. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: January 18, 2000
    Assignee: Alkermes, Inc.
    Inventor: Phillip M. Friden
  • Patent number: 6008014
    Abstract: The present invention relates to the discovery of novel genes encoding Lipid Metabolic Pathway (LMP) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
    Type: Grant
    Filed: September 4, 1996
    Date of Patent: December 28, 1999
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Carlos J. Gimeno, Susan Acton
  • Patent number: 6004535
    Abstract: A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and fusion proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and for affinity purification of MN proteins/polypeptides.
    Type: Grant
    Filed: November 7, 1994
    Date of Patent: December 21, 1999
    Assignee: Institute of Virology, Slovak Academy of Sciences
    Inventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
  • Patent number: 6001592
    Abstract: cDNAs were synthesized from the mRNA isolated from the mantle epithelial tissue of pearl oyster (Pinctada fucata) using reverse transcriptase and joined to a vector to give a cDNA library. A cDNA inserted in this cDNA library was caused to be expressed in Escherichia coli, for instance, to give a polypeptide corresponding to said cDNA. This polypeptide serves as a novel ingredient of cosmetic compositions, for instance.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: December 14, 1999
    Assignee: Mikimoto Pharmaceutical Co., Ltd.
    Inventors: Kunio Nakashima, Shu Sudo
  • Patent number: 5993829
    Abstract: There is disclosed a method of preparing a vaccine suitable for administration to humans for the prevention or treatment of cancer. The vaccine is prepared by culturing human cancer cells in a serum-free medium and recovering from the culture medium the cell surface antigens shed from the human cancer cells during culturing. After purification, the collected or recovered shed antigens are employed to produce a vaccine consisting essentially of said antigens for the treatment or prevention of human cancer.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: November 30, 1999
    Inventor: Jean-Claude Bystryn
  • Patent number: 5994504
    Abstract: The invention relates to the discovery and purification of novel vitamin D response element binding proteins and the isolation of polynucleotide sequences encoding the proteins. Vitamin D response element binding proteins are distinct from the vitamin D receptor. Vitamin D response element binding proteins can interfere with the biological activity of the vitamin D receptor and other related intracellular receptor proteins. One aspect of the invention is to provide purified vitamin D response element binding proteins. Another aspect of the invention is to provide polynucleotides encoding the vitamin D response element binding proteins of the invention and to provide polynucleotides complementary to polynucleotide coding strand. Another aspect of the invention is to provide antibodies capable of binding to the vitamin D response element binding proteins of the invention.
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: November 30, 1999
    Assignee: Cedars-Sinai Medical Center
    Inventor: John S. Adams
  • Patent number: 5994523
    Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: November 30, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Yutaka Kawakami, Steven A. Rosenberg
  • Patent number: 5985290
    Abstract: The present invention provides a method of treating cancer comprising (a) obtaining a tumor cell line, (b) modifying the tumor cell line to render it capable of producing an increased level of a cytokine relative to the unmodified tumor cell line, and (c) administering the tumor cell line to a mammalian host having at least one tumor that is the same type of tumor as that from which the tumor cell line was obtained, wherein the tumor cell line is allogeneic and is not MHC-matched to the host. The present invention also provides a pancreatic tumor cell line, a method and medium for obtaining such a tumor cell line, and a composition comprised of cells of a purified pancreatic tumor cell line.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: November 16, 1999
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Elizabeth M. Jaffee, Drew M. Pardoll, Hyam I. Levitsky
  • Patent number: 5976811
    Abstract: Antibodies for the selective immunological determination of bile acids in biological matricesPolyclonal antibodies for the selective immunological determination of bile acids in biological matrices, a process for the preparation of these antibodies, and their use in immunoassays are described.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: November 2, 1999
    Assignee: Hoescht Aktiengesellschaft
    Inventors: Stefan Mullner, Axel Hoffmann